Regulation of prostatic growth and function by peptide growth factors

Prostate

Volumn 28, Issue 6, 1996, Pages 392-405

  Culig, Zoran ^a   Hobisch, Alfred ^a   Cronauer, Marcus V ^a   Radmayr, Christian ^a   Hittmair, Anton ^b   Zhang, Ju ^a   Thurnher, Martin ^a   Bartsch, Georg ^a   Klocker, Helmut ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY OF INNSBRUCK   (Austria)

Author keywords

autocrine and paracrine mode of action; benign prostatic hyperplasia; epidermal growth factor; heparin binding growth factors; insulin like growth factors; positive and negative growth factors; prostatic carcinoma; transforming growth factors

Indexed keywords

EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR; GROWTH FACTOR; SOMATOMEDIN; TRANSFORMING GROWTH FACTOR;

ARTICLE; GENE EXPRESSION REGULATION; GROWTH REGULATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOREGULATION; MALE; PRIORITY JOURNAL; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; REGULATORY MECHANISM; TUMOR GROWTH;

ANIMALS; CELL DIVISION; DISEASE MODELS, ANIMAL; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTORS; GROWTH SUBSTANCES; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; RATS; SOMATOMEDINS; TRANSFORMING GROWTH FACTORS;

EID: 0030014202     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(199606)28:6<392::AID-PROS9>3.0.CO;2-C     Document Type: Article

References (142)

1. Isaacs JT, Coffey DS: Androgenic control of prostatic growth: Regulation of steroid levels. UICC Monogr (Prostatic Cancer) 48:112-122, 1979.
2. McKeehan WL, Adams PS, Rosser MP: Direct mitogenic effects of insulin, epidermal growth factor, glucocorticoid, cholera toxin, unknown pituitary factors and possibly prolactin, but not androgen, on normal rat prostate epithelial cells in serum-free, primary cell culture. Cancer Res 4:1998-2010, 1984.
3. Ulrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tarn AW, Lee J, Yarden Y, Liebermann TA, Schlessinger J, Downward J, Mayes ELV, Whittle N, Waterfield MD, Seeburg PH: Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A 431 epidermoid carcinoma cells. Nature 309:418-424, 1984.
4. Hill DJ: Growth factors and their cellular action. J Reprod Fertil 85:723-734, 1989.
5. Gregory H, Willshire IR, Kavanagh JP, Blacklock NJ, Chowdury S, Richards RC: Urogastrone-epidermal growth factor concentrations in prostatic fluid of normal individuals and patients with benign prostatic hypertrophy. Clin Sci 50:359-363, 1986.
6. Jacobs SC, Story MT, Sasse J, Lawson RK: Characterization of growth factors derived from the rat ventral prostate. J Urol 139:1106-1110, 1988.
7. Hiramatsu M, Kashimata M, Minami N, Sato A, Murayama M: Androgenic regulation of epidermal growth factor in the mouse ventral prostate. Biochem Int 17:311-317, 1988.
8. McKeehan WL, Adams PS, Fast D: Different hormonal requirements for androgen-independent growth of normal and tumor epithelial cells from rat prostate. In Vitro Cell Dev Biol 23:147-152, 1987.
9. Sutkowski DM, Fong C-J, Sensibar JA, Rademaker AW, Sherwood ER, Kozlowski JM, Lee C: Interaction of epidermal growth factor and transforming growth factor beta in human prostatic epithelial cells in culture. Prostate 21:133-143, 1992.
10. Levine AC, Ren M, Huber GK, Kirschenbaum A: The effect of androgen, estrogen, and growth factors on the proliferation of cultured fibroblasts derived from human fetal and adult prostates. Endocrinology 130:2413-2419, 1992.
11. Connolly JM, Rose DP: Production of epidermal growth factor and transforming growth factor-α by the androgen-responsive LNCaP human prostate cancer cell line. Prostate 16:209-218, 1990.
12. Connolly JM, Rose DP: Secretion of epidermal growth factor and related polypeptides by the DU145 human prostate cell line. Prostate 15:177-186, 1989.
13. Fowler JE Jr, Lau JLT, Ghosh L, Mills SE, Mounzer A: Epidermal growth factor and prostatic carcinoma: An immunohistochemical study. J Urol 139:857-861, 1988.
14. Taylor TB, Ramsdell JS: Transforming growth factor-α and its receptor are expressed in the epithelium of the rat prostate gland. Endocrinology 133:1306-1311, 1993.
15. Harper ME, Goddard L, Glynne-Jones E, Wilson DW, Price-Thomas M, Peeling WB, Griffiths K: An immunocytochemical analysis of TGFα expression in benign and malignant prostatic tumors. Prostate 23:9-23, 1993.
16. MacDonald A, Chisholm GD, Habib FK: Production and response of a human prostatic cancer line to transforming growth factor-like molecules. Br J Cancer 62:579-584, 1990.
17. Hofer DR, Sherwood ER, Bromberg WD, Mendelsohn J, Lee C, Kozlowski JM: Autonomous growth of androgen-independent human prostatic carcinoma cells: Role of transforming growth factor a. Cancer Res 51:2780-2785, 1991.
18. Wilding G, Valverius E, Knabbe C, Gelmann EP: Role of transforming growth factor alpha in human prostate cancer cell growth. Prostate 15:1-12, 1989.
19. Frydenberg M, Foo TMS, Jones AS, Grace J, Hensley WJ, Rogers J, Pearson BS, Raghavan D: Benign prostatic hyperplasia-video image analysis and its relationship to androgen and epidermal growth factor receptor expression. J Urol 146:872-876, 1991.
20. Ibrahim GK, Kerns B-JM, MacDonald JA, Ibrahim SN, Kinney RB, Humphrey PA, Robertson CN: Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. J Urol 149:170-173, 1993.
21. Habib FK: Peptide growth factors: A new frontier in prostate cancer. Prog Clin Biol Res 357:107-115, 1990.
22. Maygarden SJ, Strom S, Ware JL: Localization of epidermal growth factor receptor by immunohistochemical methods in human prostatic carcinoma, prostatic intraepithelial neoplasia, and benign hyperplasia. Arch Pathol Lab Med 116:269-273, 1992.
23. Davies P, Eaton CL: Binding of epidermal growth factor by human normal, hypertrophic, and carcinomatous prostate. Prostate 14:123-132, 1989.
24. Morris GL, Dodd JG: Epidermal growth factor receptor mRNA levels in human prostatic tumors and cell lines. J Urol 143:1272-1274, 1990.
25. Maddy SQ, Chisholm GD, Bussutil A, Habib FK: Epidermal growth factor receptors in human prostate cancer: Correlation with histological differentiation of the tumour. Br J Cancer 60:41-44, 1989.
26. MacDonald A, Habib FK: Divergent responses to epidermal growth factor in hormone sensitive and insensitive human prostate cancer cell lines. Br J Cancer 65:177-182, 1992.
27. Davidson NE, Gelmann EP, Lippman ME, Dickson RB: Epidermal growth factor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1:216-223, 1987.
28. Tillotson JK, Rose DP: Density-dependent regulation of epidermal growth factor receptor expression in DU 145 human prostate cancer cells. Prostate 19:53-61, 1991.
29. Schuurmans ALG, Bolt J, Mulder E: Androgens stimulate both growth rate and epidermal growth factor activity of the human prostate tumor cell LNCaP. Prostate 12:55-63, 1988.
30. Jarard DF, Blitz BF, Smith RC, Patai BL, Rukstalis DB: Effect of epidermal growth factor on prostate cancer cell line PC3 growth and invasion. Prostate 24:46-53, 1994.
31. Traish AM, Wotiz HH: Prostatic epidermal growth factor receptors and their regulation by androgens. Endocrinology 121:1461-1467, 1987.
32. Schuurmans ALG, Bolt J, Veldscholte J, Mulder E: Regulation of growth of LNCaP human prostate tumor cells by growth factors and steroid hormones. J Steroid Biochem Mol Biol 40:193-197, 1991.
33. Schuurmans ALG, Bolt J, Voorhorst MM, Blankenstein RA, Mulder E: Regulation of growth and epidermal growth factor receptor levels of LNCaP prostate tumor cells by different steroids. Int J Cancer 42:917-922, 1988.
34. Veldscholte J, Ris-Stalpers C, Kuiper GGJM, Jenster G, Berrevoets C, Claassen E, van Rooij HCJ, Trapman J, Brinkmann AO: A mutation in the ligand-binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 17:534-540, 1990.
35. Mukku VR, Stancel GM: Regulation of epidermal growth factor receptor by estrogen. J Biol Chem 260:9820-9824, 1985.
36. Murphy LJ, Sutherland RL, Stead B, Murphy LC, Lazarus L: Progestin regulation of epidermal growth factor receptor in human mammary carcinoma cells. Cancer Res 46:728-734, 1986.
37. Baker JB, Barsh GS, Carney DH, Cunningham DD: Dexamethasone modulates binding and action of epidermal growth factor in serum-free cell culture. Proc Natl Acad Sci USA 75:1882-1885, 1985.
38. Fiorelli G, De Bellis A, Longo A, Natali A, Constantini A, Serio M: Epidermal growth factor receptors in human hyperplastic prostate tissue and their modulation by chronic treatment with a gonadotropin-releasing hormone analog. J Clin Endocrinol Metab 68:740-743, 1989.
39. Scher HI, Sarkis A, Reuter V, Cohen D, Netto G, Petrylak D, Lianes P, Fuks Z, Mendelsohn J, Cordon-Cardo C: Changing pattern of expression of the epidermal growth factor receptor and transforming growth factor α in the progression of prostatic neoplasms. Clin Cancer Res 1:545-550, 1995.
40. Fong C-J, Sherwood ER, Mendelsohn J, Lee C, Kozlowski JM: Epidermal growth factor receptor monoclonal antibody inhibits constitutive receptor phosphorylation, reduces autonomous growth, and sensitizes androgen-independent prostatic carcinoma cells to tumor necrosis factor alpha. Cancer Res 52:5887-5892, 1992.
41. Connolly JM, Rose DP: Autocrine regulation of DU145 human prostate cancer cell growth factor-related polypeptides. Prostate 19:173-180, 1991.
42. Sadi MV, Walsh PC, Barrack ER: Immunohistochemical study of androgen receptors in metastatic prostate cancer - Comparison of receptor content and response to endocrine therapy. Cancer 67:3057-3064, 1991.
43. Van der Kwast TH, Schalken J, Ruizveld de Vinter JA, van Vroonhoven CCJ, Mulder E, Boersma W, Trapman J: Androgen receptors in endocrine therapy-resistant human prostate cancer. Int J Cancer 48:189-193, 1991.
44. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Androgen receptor status of lymph node metastases from prostatic carcinoma. Prostate (in press).
45. Hobisch A, Culig Z, Radmayr C, Bartsch G, Klocker H, Hittmair A: Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Res 55:3068-3072, 1995.
46. Henttu P, Vihko P: Growth factor regulation of gene expression in the human prostatic carcinoma cell line LNCaP. Cancer Res 53:1051-1058, 1993.
47. Culig Z, Hobisch A, Cronauer MV, Hittmair A, Radmayr C, Trapman J, Bartsch G, Klocker H: Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. Cancer Res 64:5474-5478, 1994.
48. Culig Z, Hobisch A, Radmayr C, Hittmair A, Cronauer MV, Bartsch G, Klocker H: Regulation of androgen-receptor mediated gene transcription in the prostatic tumor cell line DU-145 by cyclic adenosine monophosphate, insulin-like growth factor-I, phorbol ester and retinoic acid. Proc Am Assoc Cancer Res 36:1618, 1995.
49. Ignar-Trowbridge DM, Teng CT, Ross KA, Parker MG, Korach KS, McLahlan JA: Peptide growth factors elicit estrogen receptor-dependent transcriptional activation of an estrogen-responsive element. Mol Endocrinol 7:992-998, 1993.
50. Roberts AB, Sporn MB: The transforming growth factor-βs. Peptide growth factors and their receptors. In: Sporn MB, Roberts AB (eds). "Handbook of Experimental Pharmacology." Heidelberg: Springer-Verlag, 1990, pp 419-472.
51. Massague J: The TGF-β family of growth and differentiation factors. Cell 49:437-438, 1987.
52. Massague J: The transforming growth factor-β family. Annu Rev Cell Biol 6:597-641, 1990.
53. Barnard JA, Lyons RM, Moses HL: The cell biology of transforming growth factor β. Biochim Biophys Acta 1032:79-87, 1990.
54. Yang EY, Moses HL: Transforming growth factor β1-induced changes in cell migration, proliferation and angiogenesis in the chicken chorioallantoic membrane. J Cell Biol 111:731-741, 1990.
55. Roberts AB, Sporn MB, Assoian RK, Smith JM, Roche NS: Transforming growth factor type β: Rapid induction of fibrosis and angiogenesis in vivo and stimulation of collagen formation in vitro. Proc Natl Acad Sci USA 83:4167-4171, 1986.
56. Welch DR, Fabra A, Nakajima M: Transforming growth factor β stimulates mammary adenocarcinoma cell invasion and metastatic potential. Proc Natl Acad Sci USA 87:7678-7682, 1990.
57. Kehrl JH: Transforming growth factor-β: An important mediator of immunoregulation. Int J Cell Cloning 9:439-450, 1991.
58. Wilding G: Response of prostate cancer cells to peptide growth factors: Transforming growth factor-β. Cancer Surv 11:147-163, 1991.
59. Moses HL, Yang EY, Pietenpol JA: TGFβ stimulation and inhibition of cell proliferation: New mechanistic insights. Cell 63:245-247, 1990.
60. Fine A, Goldstein RH: The effect of transforming growth factor beta on cell proliferation and collagen formation by lung fibroblasts. J Biol Chem 262:3897-3902, 1987.
61. Centrella M, McCarthy TL, Canalis E: Transforming growth factor beta is a bifunctional regulator of replication and collagen synthesis in osteoblast-enriched cell cultures from fetal rat bone. J Biol Chem 262:2869-2874, 1987.
62. Hubbs AF, Hahn FF, Thomassen DG: Increased resistance to transforming growth factor beta accompanies neoplastic progression of rat tracheal epithelial cells. Carcinogenesis (Lond) 10:1599-1605, 1989.
63. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB: Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer. Cell 48:417-428, 1987.
64. Liu C, Tsao MS, Grisham JW: Transforming growth factors produced by normal and neoplastically transformed rat liver epithelial cells in culture. Cancer Res 48:850-855, 1988.
65. Jennings MT, Maciunas RJ, Carver R, Bascom CC, Juneau B, Misulis K, Moses HL: TGF-β1 and TGF-β2 are potent growth regulators for low grade and malignant gliomas in vitro: Evidence in support of an autocrine hypothesis. Int J Cancer 49:129-139, 1991.
66. Pircher R, Julien P, Lawrence DA: β-transforming growth factor is stored in human blood platelets as a latent high molecular weight complex. Biochem Biophys Res Commun 136:30-37, 1986.
67. Lyons RM, Gentry LE, Purchio AF, Moses HL: Mechanism of activation of latent recombinant transforming growth factor β1 by plasmin. J Cell Biol 110:1361-1367, 1990.
68. Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A: The serum concentration of active transforming growth factor-β is severely depressed in advanced atherosclerosis. Nature Med 1:74-79, 1995.
69. Sporn MB, Roberts AB, Wakefield LM, de Crombrugghe B: Some recent advances in the chemistry and biology of transforming growth factor-beta. J Cell Biol 105:1039-1045, 1987.
70. Franzen P, ten Dijke P, Ichijo H, Jamashita H, Schulz P, Heldin CH, Miyazono K: Cloning of a TGFβ type I receptor that forms a heteromeric complex with the TGFβ type II receptor. Cell 75:681-692, 1993.
71. Lin HY, Wang XF, Ng-Eaton E, Weinberg RA, Lodish HF: Expression cloning of the TGF-β type II receptor, a functional transmembrane serine/threonine kinase. Cell 68:775-785, 1992.
72. Laiho M, Weis FMB, Boyd FT, Ignotz RA, Massague J: Responsiveness to transforming growth factor β (TGF-β) restored by genetic complementation between cells defective in TGF-β receptors I and II. J Biol Chem 266:9108-9112, 1991.
73. Ewen ME, Sluss HK, Whitehouse LL, Livingston DM: TGF-β inhibition of Cdk4 synthesis is linked to cell cycle arrest. Cell 74:1009-1020, 1993.
74. Atfi A, Samperez S, Jouan P: Secretion of transforming growth factor-β by the immature rat prostate. Prostate 24:149-155, 1994.
75. McKeehan WL, Adams PS: Heparin-binding growth factor/prostatropin attenuates inhibition of rat prostate tumor epithelial cell growth by transforming growth factor type beta. In Vitro Cell Dev Biol 24:243-246, 1988.
76. Kyprianou N, Isaacs JT: Expression of transforming growth factor-β in the rat ventral prostate during castration-induced programmed cell death. Mol Endocrinol 3:1515-1522, 1989.
77. Kyprianou N, Isaacs JT: Identification of a cellular receptor for transforming growth factor-β in rat ventral prostate and its negative regulation by androgens. Endocrinology 123:2124-2131, 1988.
78. Anzano MA, Smith JM, McCune BK, Danielpour D, Sporn MB: Induction of transforming growth factor-β1 and β3 in rat prostate following castration. J Cell Biochem [Suppl] 16:105, 1992.
79. Story MT, Hopp KA, Meier DA, Begun FP, Lawson RK: Influence of transforming growth factor β1 and other growth factors on basic fibroblast growth factor level and proliferation of cultured human prostate-derived fibroblasts. Prostate 23:183-197, 1993.
80. Shain SA, Lin AL, Koger JD, Karaganis AG: Rat prostate cancer cells contain functional receptors for transforming growth factor-β. Endocrinology 126:818-825, 1990.
81. Steiner MS, Barrack ER: Expression of transforming growth factor-β1 in prostate cancer. Endocrinology 135:2240-2247, 1994.
82. Steiner MS, Barrack ER: Transforming growth factor-β1 overproduction in prostate cancer: Effects on growth in vivo and in vitro. Mol Endocrinol 6:15-25, 1992.
83. Matuo Y, Nishi N, Takasuka H, Masuda Y, Nishikawa K, Isaacs JT, Adams PS, McKeehan WL, Sato GH: Production and significance of TGF-β in AT-3 metastatic cell line established from the Dunning rat prostatic adenocarcinoma. Biochem Biophys Res Commun 166:840-847, 1990.
84. Merz VW, Miller GJ, Krebs T, Timme TL, Kadmon D, Park SH, Egawa S, Scardino PT, Thompson TC: Elevated TGF-β1 and β3 mRNA levels are associated with ras + myc-induced carcinomas in reconstituted mouse prostate: Evidence for a paracrine role during progression. Mol Endocrinol 5:503-513, 1991.
85. Schuurmans ALG, Bolt J, Mulder E: Androgens and transforming growth factor β modulate the growth response to epidermal growth factor in human prostate tumor cells (LNCaP). Mol Cell Endocrinol 60:101-104, 1988.
86. Wilding G, Zugmeier G, Knabbe C, Flanders KC, Gelmann E: Differential effects of transforming growth factor beta on human prostate cancer cells in vitro. Mol Cell Endocrinol 62:79-87, 1989.
87. Watts RG, Ware JL: Isolation and characterization of transforming growth factor beta response variants from human prostatic tumor cell lines. Prostate 21:223-237, 1992.
88. Thompson TC, Truong LD, Timme TL, Kadmon D, McCune BK, Flanders KC, Scardino PT, Park SH: Transforming growth factor β1 as a biomarker for prostate cancer. J Cell Biochem 16:54-61, 1992.
89. Truong LD, Kadmon D, McCune BK, Flanders KC, Scardino PT, Thompson TC: Association of transforming growth factor-β1 with prostate cancer: A immunohistochemical study. Hum Pathol 24:4-9, 1993.
90. Bang Y, Kim SJ, Danielpour D, O'Reilly MA, Kim KY, Myers CE, Trepel JB: Cyclic AMP induces transforming growth factor β2 gene expression and growth arrest in the human androgen-independent prostate carcinoma cell line. Proc Natl Acad Sci USA 89:3556-3560, 1992.
91. Esch F, Baird A, Ling N, Ueno N, Hill F, Denoroy L, Klepper R, Gospodarowicz D, Böhlen P, Guillemin R: Primary structure of bovine pituitary basic fibroblast growth factor (FGF) and comparison with the amino-terminal sequence of bovine brain acidic FGF. Proc Natl Acad Sci USA 82:6507-6511, 1985.
92. Saksela O, Moscatelli D, Sommer A, Rifkin DB: Endothelial cell-derived heparan sulfate binds basic fibroblast growth factor and protects it from proteolytic degradation. J Cell Biol 107:743-751, 1988.
93. Ingber DE, Folkman J: Mechanochemical switching between growth and differentiation during fibroblast growth factor-stimulated angiogenesis in vitro: Role of extracellular matrix. J Cell Biol 109:317-330, 1990.
94. Partanen J, Makela TP, Eerola E, Korhonen J, Hirvonen H, Claesson-Welsh L, Alitalo K: FGFR-4, a novel acidic fibroblast growth factor receptor with a distinct expression pattern. EMBO J 10:1347-1354, 1991.
95. Givol D, Yayon A: Complexity of FGF receptors: Genetic basis for structural diversity and functional specificity. FASEB J 6:3362-3369, 1992.
96. Mansson P-E, Adams P, Kan M, McKeehan WL: Heparin-binding growth factor gene expression and receptor characteristics in normal rat prostate and two transplantable rat prostate tumors. Cancer Res 49:2485-2494, 1989.
97. Mori H, Maki M, Oishi K, Jaye M, Igarashi K, Yoshida O, Hatanaka M: Increased expression of genes for basic fibroblast growth factor and transforming growth factor type β2 in human benign prostatic hyperplasia. Prostate 16:71-80, 1990.
98. Story MT, Sasse J, Jacobs SC, Lawson RK: Prostatic growth factor: Purification and structural relationship to basic fibroblast growth factor. Biochemistry 36:3843-3849, 1987.
99. Mydlo JH, Bulbul MA, Richon VM, Heston WDW, Fair WR: Heparin-binding growth factor isolated from human prostatic extracts. Prostate 12:343-355, 1988.
100. Story MT, Livingston B, Baeten L, Swartz SJ, Jacobs SC, Begun FP, Lawson RK: Cultured human prostate-derived fibroblasts produce a factor that stimulates their growth with properties indistinguishable from basic fibroblast growth factor. Prostate 15:355-365, 1989.
101. Nishi N, Matuo Y, Kunitomi K, Takenaka I, Usami M, Kotake T, Wada F: Comparative analysis of growth factors in normal and pathologic human prostates. Prostate 13:39-48, 1988.
102. Begun FP, Story MT, Hopp KA, Shapiro E, Lawson RK: Regional concentration of basic fibroblast growth factor in normal and benign hyperplastic human prostates. J Urol 153:839-843, 1995.
103. Muller WJ, Lee FS, Dickson C, Petters G, Pattengale P, Leder P: The int-2 gene product acts as an epithelial growth factor in transgenic mice. EMBO J 9:907-913, 1990.
104. Deering RE, Bigler SA, Brown M, Brawer MK: Microvascularity in benign prostatic hyperplasia. Prostate 26:111-115, 1995.
105. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 13:4513-4522, 1993.
106. Matuo Y, McKeehan WL, Yan GC, Nikolaropoulos S, Adams PS, Fukabori Y, Yamanaka H, Gaudreau J: Potential role of HBGF (FGF) and TGF-β on prostate growth. Adv Exp Med Biol 324:107-114, 1992.
107. Nakamoto T, Chang C, Li A, Chodak GW: Basic fibroblast growth factor in human prostate cancer cells. Cancer Res 52:571-577, 1992.
108. Cleave ME, Hsieh JT, von Eschenbach AC, Chung LWK: Prostate and bone fibroblasts induce human prostate cancer growth in vivo: Implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 147:1151-1159, 1992.
109. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim E, Hopwood VL, Pathak S, von Eschenbach AC, Chung LWK: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 54:2577-2581, 1994.
110. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS: The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 145:199-202, 1991.
111. Gospodarowicz D, Ferrara N, Schweigerer L, Neufeld G: Structural characterization and biological functions of fibroblast growth factor. Endocr Rev 8:95-114, 1987.
112. Bigler SA, Deering RE, Brawer MK: A quantitative morphometric analysis of the microcirculation in prostate carcinoma. Hum Pathol 24:220-226, 1993.
113. Weidner N, Carroll PR, Flax I, Blumenfeld W, Folkman J: Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol 143:401-420, 1993.
114. Katz AE, Benson MC, Wise GJ, Olsson CA, Bandyk MG, Sawczuk IS, Tomashefsky P, Buttyan R: Gene activity during the early phase of androgen-stimulated rat prostate regrowth. Cancer Res 49:5889-5894, 1989.
115. Harris SE, Smith RG, Zhou H, Mansson PE, Malark M: Androgens and glucocorticoids modulate heparin-binding growth factor-I mRNA accumulation in DDT1 cells as analyzed by in situ hybridization. Mol Endocrinol 3:1839-1844, 1989.
116. Hall JA, Harris MA, Malark M, Mansson PE, Zhou H, Harris SE: Characterization of the hamster DDT-1 cell aFGF/HBGF-I gene and cDNA and its modulation by steroids. J Cell Biochem 43:17-26, 1990.
117. Geller J, Sionit LR, Baird A, Kohls M, Connors KM, Huffman RM: In vivo and in vitro effects of androgen on fibroblast growth factor-2 concentrations in the human prostate. Prostate 25:206-209, 1994.
118. Zuck B, Goepfert C, Nedlin-Chittka A, Sohrt K, Voight KD, Knabbe C: Regulation of fibroblast growth factor-like proteins in the androgen-responsive human prostate carcinoma cell line LNCaP. J Steroid Biochem Mol Biol 41:659-663, 1992.
119. Van G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal to epithelial cell andromedin. Mol Endocrinol 6:2123-2128, 1992.
120. Miki T, Bottaro DP, Fleming TP, Smith CL, Burgess WH, Chan AML, Aaronson SA: Determination of ligand-binding specificity by alternative splicing: Two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci USA 89:246-250, 1992.
121. Chang SM, Chung LWK: Interaction between prostatic fibroblast and epithelial cells in culture: Role of androgen. Endocrinology 125:2719-2727, 1989.
122. Aland ET, Rubin JS, Young P, Chedid M, Ron D, Aaronson SA, Cunha GR: Keratinocyte growth factor functions in epithelial induction during seminal vesicle development. Proc Natl Acad Sci USA 91:1074-1078, 1994.
123. Daughaday WH, Rotwein P: Insulin-like growth factors I and II. Peptide, messenger ribonucleic acid and gene structures, serum, and tissue concentrations. Endocr Rev 10:68-91, 1989.
124. Murphy LJ, Friesen HG: Differential effects of estrogen and growth hormone on uterine and hepatic insulin-like growth factor I gene expression in the ovariectomised hypophysectomised rat. Endocrinology 122:325-332, 1988.
125. Rechler MM, Nisley SP: Insulin-like growth factor/somatomedin receptor subtypes: Structure, function and relationships to insulin receptors and IGF carrier proteins. Horm Res 24:152-159, 1986.
126. Czech MP: Signal transmission by the insulin-like growth factors. Cell 59:235-238, 1989.
127. Cohen P, Peehl DM, Lamson G, Rosenfeld R: Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 73:401-407, 1991.
128. Perkel VS, Mohan S, Baylink SJ, Linkhart TA: An inhibitory insulin-like growth factor binding protein (IN-IGFBP) from human prostatic cell conditioned medium reveals N-terminal sequence identity with bone derived IN-IGFBP. J Clin Endocrinol Metab 71:533-535, 1990.
129. Barni T, Vannelli BG, Sadri R, Pupilli C, Ghiandi P, Rizzo M, Selli C, Serio M, Fiorelli G: Insulin-like growth factor-I (IGF-I) and its binding protein IGFBP-4 in human prostatic hyperplastic tissue: Gene expression and its cellular localization. J Clin Endocrinol Metab 78:778-783, 1994.
130. Cohen P, Peehl DM, Baker B, Liu F, Hintz RL, Rosenfeld RG: Insulin-like growth factor axis abnormalities in prostatic stromal cell from patients with benign prostatic hyperplasia. J Clin Endocrinol Metab 79:1410-1415, 1994.
131. Iwamura M, Sluss PM, Casamento JB, Cockett ATK: Insulin-like growth factor I: Action and receptor characterization in human prostate cancer cell lines. Prostate 22:243-252, 1993.
132. Connolly JM, Rose DP: Regulation of DU145 human prostate cancer cell proliferation by insulin-like growth factors and its interaction with the epidermal growth factor autocrine loop. Prostate 24:167-175, 1994.
133. Bhaumick B, George D, Bala RM: Potentiation of epidermal growth factor-induced differentiation of cultured human placental cells by insulin-like growth factor-I. J Clin Endocrinol Metab 74:1005-1011, 1992.
134. Clemmons DR: Multiple hormones stimulate the production of somatomedin by cultured human fibroblasts. J Clin Endocrinol Metab 58:850-856, 1984.
135. Centrelia M, McCarthy TL, Canalis E: Receptors for insulin-like growth factors-I and -II in osteoblast enriched cultures from fetal rat bone. Endocrinology 126:39-44, 1990.
136. Bichell DP, Rotwein P, McCarthy TL: Prostaglandin E2 rapidly stimulates insulin-like growth factor-I gene expression in primary rat osteoblastic cultures: Evidence for transcriptional control. Endocrinology 133:1020-1028, 1993.
137. Pietrzkowski Z, Mulholland G, Cornelia L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 53:1102-1106, 1993.
138. Polychronakos C, Janthly U, Lehoux J-G, Koutsilieris M: Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: Characterization of the receptors involved. Prostate 19:313-321, 1991.
139. Cohen P, Peehl DM, Stamey TA, Wilson KF, Clemmons DR, Rosenfeld RG: Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab 76:1031-1035, 1993.
140. Kanety H, Madjar Y, Dagan Y, Levi J, Papa MZ, Pariente C, Goldwasser B, Karasik A: Serum insulin-like growth factor binding protein-2 is increased in patients with prostatic carcinoma: Correlation with serum prostate-specific antigen. J Clin Endocrinol Metab 77:229-233, 1993.
141. Cohen P, Grawes HCB, Peehl DM, Kamarli M, Giudice LC, Rosenfeld RG: Prostate-specific antigen is an insulin-like growth factor-binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75:1046-1053, 1992.
142. Marcelli M, Haidacher SJ, Plymate SR, Birnbaum RS: Altered growth and insulin-like growth factor-binding protein-3 production in PC3 prostate carcinoma cells stably transfected with a constitutively active androgen receptor complementary deoxyribonucleic acid. Endocrinology 136:1040-1048, 1995.